• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
  • About Us
  • Contact Us
  • Billing Portal
SPRINT® PNS System

SPR Therapeutics

SPRINT PNS System

  • Product
  • For Physicians
    • Clinical Outcomes & References
    • Implant Procedure Videos
    • Video Resources
    • SPRcare Reimbursement
    • Important Safety Information
    • MRI Safety Information
    • Promotional Marketing Toolkit
  • For Patients
    • Patient Stories
    • Patient Resources
    • Recursos para pacientes
    • MicroLead™ Safety
    • MRI Safety Information
  • Clinical Trials
  • News & Events
    • News
    • Events
    • Press Room
  • Careers

How May Temporary 60-Day PNS Treatment Improve Identification of Delayed Responders and Non-Responders to Neurostimulation?

April 28, 2022

Peripheral nerve stimulation (PNS) has broad applications for pain relief and has been successfully used to treat myriad types of pain. Current conventional neurostimulation systems for pain relief typically involve a brief (e.g., ≤7-10-day) trial to assess presumed effectiveness prior to permanent system implantation. Conventional trials are typically considered to be positive if patients report a certain threshold of pain relief (e.g., ≥50% pain relief), and positive short trials are then often followed by implantation of a permanent neurostimulator. While patients may achieve successful long-term pain relief from a permanently implanted system, many experience inadequate pain relief resulting in system failure and explant. Overall, low trial-to-implant conversion rates and high rates of explant due to inadequate pain relief suggest that improved real-world patient identification strategies are needed to distinguish likely responders and non-responders to neurostimulation such that, if sustained relief is not achieved from a short-term PNS treatment, patients and physicians are better informed before making the decision to implant a permanent system.

In a recently published manuscript in the Journal of Pain Research entitled, “60-Day PNS Treatment May Improve Identification of Delayed Responders and Delayed Non-Responders to Neurostimulation for Pain Relief”, Dr. Ramana Naidu and colleagues — Drs. Sean Li, Mehul Desai and Samir Sheth along with members of SPR Therapeutics’ R&D team, Nathan Crosby, PhD, and Joseph Boggs, PhD — explored how SPRINT PNS, a 60-day temporary PNS system, could be leveraged to help physicians characterize patient responsiveness to neurostimulation. The study represented the first analysis of real-world evidence showing the evolution of pain relief in patients during a temporary, 60-day PNS treatment for pain relief.

By evaluating patient reports of pain relief throughout the course of the 60-day PNS treatment period, the study authors found that patients could be categorized into four response profiles:

  1. Early Responders: patients who reported ≥50% pain relief throughout the 60-day treatment period;
  2. Early Non-responders: patients who never achieved ≥50% pain relief during the 60-day treatment period;
  3. Delayed Responders: patients who reported less than 50% pain relief within the first two weeks but ultimately achieved ≥50% pain relief before the end of the 60-day treatment period; and
  4. Delayed Non-responders: patients who reported ≥50% pain relief within the first two weeks but ultimately fell below 50% pain relief by the end of the 60-day treatment period.

Early responders and early non-responders displayed patterns within the first two weeks of stimulation that were highly indicative of their final disposition at the end of the 60-day treatment. Meanwhile, delayed responders and delayed non-responders, who represented nearly 40% of all patients, evolved over the course of the 60-day treatment such that their early responses in the first two weeks did not reliably predict whether the treatment would ultimately be considered successful after up to 60 days.

 The potential clinical benefits of improving patient identification strategies are significant. In the case of delayed responders, clinical and real-world evidence suggest that responders to 60-day PNS treatment have the potential to achieve sustained benefits that may long outlast the 60-day treatment period, obviating the need for a permanently implanted conventional neurostimulation system in many cases. In patients for whom pain returns soon after the end of the 60-day treatment, success during the temporary 60-day PNS treatment could also validate trialing a permanent implant. Therefore, whereas delayed responders undergoing a brief (≤7-10-day) temporary stimulation period may be spuriously categorized as non-responders and be forced to seek alternate therapeutic options, a 60-day treatment period may increase patient access to PNS by either providing sustained pain relief or providing evidence for the potential utility of a permanent implant. Conversely, the potential costs and risks are significant for delayed non-responders who initially present strong false positive responses during the brief trial period, and on that basis are qualified for permanent implantation that is ultimately unlikely to be successful. Identifying delayed non-responders more effectively, potentially with a longer (i.e., 60-day) treatment period, could therefore help avoid the physical, psychological and financial impacts associated with implantation, revision, and explant of neurostimulator systems in non-responsive patients.

These concepts are illustrated in the figure below, showing the potential outcomes of positive and negative trials with conventional PNS systems, as well as the potential improvements in patient identification enabled by a longer, 60-day treatment period. These scenarios support the importance of an extended 60-day temporary peripheral nerve stimulation period to help inform stepwise treatment strategies that may optimize outcomes and cost-effectiveness.

The potential outcomes of positive and negative conventional, brief PNS trials are shown above, with many patients proceeding to permanent implant but ultimately failing to achieve adequate pain relief and requiring system explant. A temporary, 60-day PNS treatment may improve identification of responders, providing some with sustained relief, while either obviating or validating the potential utility of permanently implanted PNS in others.

Click to read the full manuscript in the Journal of Pain Research, Volume 15


The SPRINT PNS System is indicated for up to 60 days for: (i) Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; (ii) Symptomatic relief of post-traumatic pain; and (iii) Symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to be placed in the region innervated by the cranial and facial nerves. 

Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only.  

Important safety & risk information: https://bit.ly/2FU92NH


Share this post:

Share on Twitter Share on Facebook Share on LinkedIn Share on SMS Share on Email
Category: NewsTag: 60-day percutaneous PNS, PNS, SPRINT PNS, SPRINT PNS System
Previous Post:The PNS Trifecta: All Three SPRINT® PNS System Abstracts Submitted to ASRA 2021 Pain Medicine Meeting Receive President’s Choice Award
Next Post:Real-world Study of SPRINT 60-day Peripheral Nerve Stimulation (PNS) Corroborates Published Clinical Study Results

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Sidebar

Archives

Recent News

SPR Therapeutics Receives 510(k) Clearance of Technological Advancements and an Expanded Intended Patient Population for the SPRINT® PNS System

Dr. Samir Sheth discusses how the SPRINT® PNS System has impacted his approach to treating patients with chronic head and neck pain

SPR Therapeutics Debuts Occipital Nerve Stimulation Data at ASRA 2022

A Discussion on Pain Management Options for Patients with Breast Cancer with Dr. Amitabh Gulati

Real-World Retrospective Review of Axial Neck Pain Relief Following Peripheral Nerve Stimulation of Cervical Medial Branch Nerves

Tags

60-day percutaneous PNS acute pain Back Pain back pain treatment cancer pain chronic back pain Chronic Pain clinical study Dr. Mehul Desai drug-free EY award hip pain low back pain medial branch Neuromodulation Non-opioid oncological pain opioid alternative Pain pain appointment pain physician pain relief pain treatment Patients Patient Story peripheral nerve stimulation permanent PNS implant phantom limb pain PNS PNS training post-amputation pain Press release radiofrequency ablation recondition CNS reduced opioids research Research study residual limb pain RFA Shoulder Pain SPRINT PNS SPRINT PNS System temporary pns Training lab webinar
SPRINT® PNS System

22901 Millcreek Blvd, Suite 500
Cleveland, OH 44122
(844) 378-9108 Phone
(216) 803-0777 Fax

Top Work Places 2022

Quick Links

  • Product
  • For Physicians
  • For Patients
  • Clinical Trials
  • News & Events
  • Careers
  • About Us
  • Contact Us

Legal Links

  • Privacy Statement
  • Terms of Use
  • CPRA Requests
  • Important Safety Information
  • Compliance
  • FCOI Policy
  • Product Terms & Conditions
  • Patent Information

Recent News Headlines

SPR Therapeutics Receives 510(k) Clearance of Technological Advancements and an Expanded Intended Patient Population for the SPRINT® PNS System

Sprint Regional Lab Fluoro Only – Boston

Sprint Regional Lab – Boston

SPRINT PNS Regional Lab & APP Program: Kansas City

The SPRINT PNS System is indicated for up to 60 days for: (i) Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; (ii) Symptomatic relief of post-traumatic pain; and (iii) Symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to be placed in the region innervated by the cranial and facial nerves. Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only.

View References for support of all claims.

The SPRINT® PNS System, MicroLead™, OnePass Introducer™, Rethink Your Pain Strategy™, Outsmart Pain™, Sustained Pain Relief Starts Here™, Life. Get Back to It.™ and SPR® are registered or common law trademarks of SPR Therapeutics, Inc.


Copyright © 2023 SPR Therapeutics. All Rights Reserved.

This website is intended only for US and Canadian residents 18 years of age and older. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
Save & Accept
Powered by CookieYes Logo